Eva Natukunda

Kampala, C, Uganda

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.

Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.

Journal: The Pediatric infectious disease journal

Published: February 24, 2026

Correction: Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.

Correction: Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.

Journal: PloS one

Published: December 16, 2025

Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda.

Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in Uganda.

Journal: PLOS global public health

Published: May 23, 2025

Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.

Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.

Journal: The New England journal of medicine

Published: May 14, 2025

Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study.

Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study.

Journal: The Pediatric infectious disease journal

Published: April 18, 2025

Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy.

Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: December 11, 2024

High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV.

High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV.

Journal: AIDS research and therapy

Published: September 25, 2024

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg.

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg.

Journal: Journal of the International AIDS Society

Published: April 18, 2024

Comparison between dual energy X-ray absorptiometry and calcaneal quantitative ultrasound for determining bone mineral density in children living with HIV in uganda: A cross- sectional study.

Comparison between dual energy X-ray absorptiometry and calcaneal quantitative ultrasound for determining bone mineral density in children living with HIV in uganda: A cross- sectional study.

Journal: BMC pediatrics

Published: December 07, 2023

Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.

Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.

Journal: The lancet. HIV

Published: June 29, 2023

Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.

Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.

Journal: PloS one

Published: February 23, 2023

Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.

Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: March 18, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026